Therapeutic Anti-Angiogenesis for Malignant Brain Tumors

Kirsch, Matthias; Santarius, T.; Black, Peter McL.; Schackert, Gabriele

doi:10.1159/000055122

Cited by 19 publications

(20 citation statements)

References 77 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A number of substances that modulate angiogenesis have been employed to treat brain tumours in vivo, such as fumagillin derivates [81,82] , the combination of heparin and angiostatic steroids [83] , and antibiotics (Table 2) [84] . O'Reilly et al [85] has described a plasminogen-derived substance, termed angiostatin, as a highly specific inhibitor of tumour-related endothelial cell proliferation and the most potent antiangiogenic substance so far [85] .…”

Section: Implication Of Glioma-derived Cytokines In Angiogenesismentioning

confidence: 99%

Role of Cytokines in the Regulation of Glioma Tumour Growth and Angiogenesis

Piperi¹,

Zisakis²,

Lea³

et al. 2005

American J. of Immunology

View full text Add to dashboard Cite

Malignant glioblastomas are the most common type of primary brain tumors accounting for more than 50% of all intracranial gliomas. Due to their aggressive nature, recurrent growth, and their extremely poor prognosis for survival, research approaches have made little progress in advancing treatment of these tumours which have the ability of both modulating host immune function and neutralizing immune-based therapies. Patients with gliomas exhibit a broad suppression of cellmediated immunity by a shift in cytokine secretion from Th1-type immune response to Th2, with an increased secretion of anti-inflammatory cytokines been observed, possibly due to release of a variety of immunosuppressive factors. Furthermore, secretion of specific cytokines stimulates angiogenic processes which contribute to the development of malignancy of these tumours. This review summarizes the role of cytokines in glioma growth and invasion, and indicates how specific cytokines may affect angiogenesis.

show abstract

Section: Implication Of Glioma-derived Cytokines In Angiogenesismentioning

confidence: 99%

Role of Cytokines in the Regulation of Glioma Tumour Growth and Angiogenesis

Piperi¹,

Zisakis²,

Lea³

et al. 2005

American J. of Immunology

View full text Add to dashboard Cite

show abstract

“…Glial tumors are among the most malignant intrinsic brain tumors, characterized by excessive proliferation, angiogenesis, and infiltration (10). Only few reports illuminate the possible function of LRP1 in these aggressive tumors, and results obtained are rather controversial (11).…”

Section: Introductionmentioning

confidence: 99%

α2-Macroglobulin Inhibits the Malignant Properties of Astrocytoma Cells by Impeding β-Catenin Signaling

et al. 2010

View full text Add to dashboard Cite

Targets that could improve the treatment of brain tumors remain important to define. This study of a transformation-associated isoform of α2-macroglobulin (A2M*) and its interaction with the low-density lipoprotein receptor-related protein-1 (LRP1) suggests a new mechanism for abrogating the malignant potential of astrocytoma cells. LRP1 bound A2M* found to be associated with an inhibition of tumor cell proliferation, migration, invasion, spheroid formation, and anchorage-independent growth. Transcriptional studies implicated effects on the Wnt/β-catenin signaling pathway. Notably, LRP1 antibodies could phenocopy the effects of A2M*. Our findings suggest a pathway of tumor suppression in astrocytoma that might be tractable to therapeutic exploitation. Cancer Res; 70(1); 277-87. ©2010 AACR.

show abstract

“…This fact renders the endothelial cellular compartment an attractive target for antineoplastic treatment. Endothelial cells are a much more homogenous cellular population than malignant astrocytes, and are less subject to drug resistance [118]. Moreover, these cells are easily reached by drugs in the systemic circulation.…”

Section: Angiogenesis Inhibitorsmentioning

confidence: 99%

Chemotherapy and Delivery in the Treatment of Primary Brain Tumors

Mathieu

Fortin²

2007

CCP

View full text Add to dashboard Cite

Malignant astrocytomas are aggressive neoplasms with a dismal prognosis despite optimal treatment. Maximal resective surgery is traditionally complemented by radiation therapy. Chemotherapy is typically used on patients with tumor recurrence, when their functional status is congruent with further treatment. The classic agents used are nitrosoureas, but temozolomide is gradually taking a more prominent role recently. New agents, biological modifiers, are increasingly used in clinical trials in an effort to affect the intrinsic biologic aberrations harboured by tumor cells. These drugs comprise differentiation agents, anti-angiogenic agents, matrix-metalloproteinase inhibitors and signal transduction inhibitors, among others. The issue of chemotherapy delivery is also crucial. Classically, agents are administered either intravenously or orally. In an effort to circumvent the obstacle imposed by the blood-brain barrier, investigators are actively working on more invasive methods of delivery, namely intra-arterial infusion with or without blood-brain barrier disruption or direct intra-cerebral administration, with clysis or drug-impregnated wafers. This article reviews the standard cytotoxic agents that have been used to treat malignant astrocytomas, and the different combination regimen offering promise. In addition, recent advances with biological modifiers are also discussed, along with alternate methods to deliver the agents more efficiently across the blood-brain barrier.

show abstract

Therapeutic Anti-Angiogenesis for Malignant Brain Tumors

Cited by 19 publications

References 77 publications

Role of Cytokines in the Regulation of Glioma Tumour Growth and Angiogenesis

Role of Cytokines in the Regulation of Glioma Tumour Growth and Angiogenesis

α2-Macroglobulin Inhibits the Malignant Properties of Astrocytoma Cells by Impeding β-Catenin Signaling

Chemotherapy and Delivery in the Treatment of Primary Brain Tumors

Contact Info

Product

Resources

About